Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk

A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason score of 7), which has the potential to stratify these patients into different risk groups. Clin Cancer Res; 23(1); 6–8. ©2016 AACR. See related article by Sinnott et al., p. 81

[1]  Jennifer R. Rider,et al.  Prognostic Utility of a New mRNA Expression Signature of Gleason Score , 2016, Clinical Cancer Research.

[2]  M. Cooperberg,et al.  Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. , 2016, The Journal of molecular diagnostics : JMD.

[3]  David Y. Lu,et al.  Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. , 2014, The Journal of urology.

[4]  P. Febbo,et al.  A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.

[5]  E. Crawford,et al.  Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry , 2014, Current medical research and opinion.

[6]  Anirban P. Mitra,et al.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.

[7]  M. Cooperberg,et al.  Active surveillance for prostate cancer: a systematic review of the literature. , 2012, European urology.

[8]  T. Golub,et al.  mRNA expression signature of Gleason grade predicts lethal prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[10]  Kirsten L. Greene,et al.  Outcomes of active surveillance for men with intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.